Member Info for dafad

That's assuming you have 7p warrants

So Myles you are looking at a share price of between £2.10 and £3.50

I'll be happy with that!

Agreed-but could they forward sell the sgares they are about to recieve?

So in effect it could be that others have forward sold shares but are yet to notify Mka re warrant excercisr

Mka have only been notified by certain parties about warrant excercise-there may be others who haven't.

the "Company" or "Mkango"), announces that it has received exercise notices from certain Mkango warrant holders to exercise 600,000 warrants over common shares in the

If the warrants/shares have been forward sold then we may see another rns re warrants very soon

Https://www.londonstockexchange.com/news-article/MKA/exercise-of-warrants/17136111

There was a 1 share code yesterday for the belivers!

So where will Tesla invest?

Last push before w end press?

Just bought another533,606 @.3198

Not showing yet!

Over 3 million held now!

I do hold shares in Svns -but check out this mornings rns -raised at premium

But what is more interesting is they are involved i ai/medicen and moreso into addiction

Let's hope none of the big pharmas come along with an offer before we at least reach double digits!

Anthony Tennyson, Chief Executive Officer of Solvonis, commented: "We are pleased to receive this investment from our largest and longest-standing shareholders. Their continued conviction supports our strategy to lead innovation in addiction and mental health therapeutics, including the acceleration of our proprietary AI-supported discovery platform. This funding enables acceleration of building a differentiated pipeline in stimulant use and depressive disorders."

Solvonis Therapeutics plc (LSE: SVNS), a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders, announces that it has raised gross proceeds of £1.0 million through a direct subscription (the "Subscription") for 333,333,334 new ordinary shares of £0.001 each in the capital of the Company (the "Subscription Shares") at a price of 0.3 pence per Subscription Share (the "Issue Price"). The Issue Price is approximately a 3.5% premium to the closing price of 0.29 pence per share on 10 July 2025.

The Subscription is being undertaken by three of the Company's largest shareholders, reflecting their continued strong support for Solvonis' strategy and execution.

Rns out

Imho

Maybe he did not want any confluct of intetest as capai will be promoting author42 to boundless?

He resigned from Boundless on June 19th 2025

If they have finished selling for now then expect a bounce today